General practice pharmacist scheme evaluation indicates ‘improved capacity’ as the main benefit

General practice pharmacist scheme evaluation indicates ‘improved capacity’ as the main benefit

July 31 2018 General practices employing pharmacists are citing improved capacity to see patients...

Asthma deaths levels increase by a quarter in a decade

Asthma deaths levels increase by a quarter in a decade

July 26 2018 There were 1,320 deaths due to asthma in England and Wales in 2017, the highest...

NPA and Age UK ask for help on building polypharmacy dossier

NPA and Age UK ask for help on building polypharmacy dossier

July 25 2018 The National Pharmacy Association is asking its members for case studies on...

Pharmacy bodies welcome Health Secretary’s pledge to invest in community pharmacy

Pharmacy bodies welcome Health Secretary’s pledge to invest in community pharmacy

July 24 2018 New Health Secretary Matt Hancock has called for investment in primary care and...

NHS Digital seeks views on SCR with Additional Information

NHS Digital seeks views on SCR with Additional Information

July 24 2018 A survey to assess the benefits and/or disadvantages of health professionals...

  • General practice pharmacist scheme evaluation indicates ‘improved capacity’ as the main benefit

    General practice pharmacist scheme evaluation indicates ‘improved capacity’ as the main benefit

    Tuesday, 31 July 2018 15:31
  • Asthma deaths levels increase by a quarter in a decade

    Asthma deaths levels increase by a quarter in a decade

    Thursday, 26 July 2018 15:08
  • NPA and Age UK ask for help on building polypharmacy dossier

    NPA and Age UK ask for help on building polypharmacy dossier

    Wednesday, 25 July 2018 13:46
  • Pharmacy bodies welcome Health Secretary’s pledge to invest in community pharmacy

    Pharmacy bodies welcome Health Secretary’s pledge to invest in community pharmacy

    Tuesday, 24 July 2018 12:53
  • NHS Digital seeks views on SCR with Additional Information

    NHS Digital seeks views on SCR with Additional Information

    Tuesday, 24 July 2018 12:41

Umesh Modi is a chartered accountant, and Pamini Jatheeskumar is a chartered certified accountant at Silver Levene...
  Don Lavoie is alcohol programme manager at Public Health England and Gul Root is lead...
Don Lavoie is alcohol programme manager at Public Health England and Gul Root is lead pharmacist, Health and Wellbeing Directorate, Public Health England
More inWhite Papers  

A pregnant lady imageFebruary 28 2018

The Government has launched a review into how the NHS responds to reports from patients about side effects from treatments.

It will consider three treatments that have had been brought to prominence through patient-led campaigns: 

  • sodium valproate;
  • the Primodos hormone pregnancy test, which was used up until 1978;
  • the use of vaginal mesh.

Announcing the review, Health Secretary Jeremy Hunt said: “Over the years, there have been significant concerns raised by individuals and campaign groups about the potentially harmful effects of 3 products used by the NHS. The response they have received from those in positions of authority has not always been good enough.

“Patients and their families have had to spend too much time and energy campaigning for answers in a way that has added insult to injury for many. I want to see if we can establish a fairer and quicker way of resolving these concerns both now and in the future.”

A former health minister Baroness Cumberlege, who is also Vice Chair of the All-Party Pharmacy Group, will chair the review. She has been asked to consider:

  • whether any further action is needed relating to the complaints around the products;
  • the processes followed by the NHS and its regulators when patients report a problem;
  • how to make sure communication between the different groups involved is good.

Baroness Cumberlege, said: “I look forward to undertaking this tremendously important review and in particular to working with patients to ensure that our health system learns from those it may have failed. It’s essential that voices aren’t just listened to, but properly heard, and that whenever appropriate, the system promptly learns lessons and makes changes.”

Epilepsy Action’s deputy chief executive Simon Wigglesworth said the announcement “marks a major breakthrough for the thousands of women with epilepsy who’ve campaigned for change around sodium valproate.

“We urge Baroness Cumberlege to fully consider the decades of evidence provided by campaigning groups, including Epilepsy Action. This will help those families who’ve suffered can get some closure. It will also help women with epilepsy make fully-informed decisions about their treatment and planning a family.”

Links:
Department of Health and Social Care announcement  
Epilepsy Action statement       

Practice News

July 31 2018 General practices employing pharmacists are citing improved capacity to see patients and workload changes as the main benefits of the scheme.
July 25 2018 Switching to sulfonylureas in type 2 diabetes has been linked with an increased risk of complications compared with staying on metformin, a BMJ study has concluded. However, the study has...